Health Fair 11 at the Fair Offers Healthy Options to State Fair Goers
15 août 2019 17h35 HE
|
Minnesota Health Fairs Inc.
GOLDEN VALLEY, Minn., Aug. 15, 2019 (GLOBE NEWSWIRE) -- The Minnesota State Fair is all about tradition. Fairgoers have their must-eat food(s!), their tried-and-true route around the fairgrounds,...
Food Allergies Are Top Concern for Families As They Prepare for Back-to-School
15 août 2019 08h21 HE
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) released a report of findings from its “My Life With Food Allergy” study. As children...
Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
17 mai 2019 13h25 HE
|
Intrommune Therapeutics
New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Quick Umbrellux DAO Test Reveals If That Reaction Is Really Histamine Intolerance And Not A Food Allergy
13 mai 2019 09h30 HE
|
Umbrellux DAO
ANN ARBOR, Mich., May 13, 2019 (GLOBE NEWSWIRE) -- Food Allergy Awareness Week is the perfect time to determine if you may be mislabeling your body’s reaction to certain foods. Umbrellux DAO offers...
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
08 mars 2019 10h01 HE
|
Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
US BioTek Laboratories Announces Jack Frausing as CEO
14 janv. 2019 08h00 HE
|
US BioTek
SEATTLE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- US BioTek Laboratories (US BioTek) announced today the appointment of a new President and CEO, Jack Frausing. Frausing assumes the leadership from...
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
08 nov. 2018 16h44 HE
|
Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
06 sept. 2018 07h11 HE
|
Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
15 mai 2018 12h00 HE
|
Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
09 mai 2018 10h36 HE
|
Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...